Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-064669
Filing Date
2023-03-08
Accepted
2023-03-08 17:11:04
Documents
12
Period of Report
2022-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A d464178d8ka.htm   iXBRL 8-K/A 27961
  Complete submission text file 0001193125-23-064669.txt   160934

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20221216.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20221216_lab.xml EX-101.LAB 19443
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20221216_pre.xml EX-101.PRE 12136
6 EXTRACTED XBRL INSTANCE DOCUMENT d464178d8ka_htm.xml XML 4823
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39536 | Film No.: 23717006
SIC: 2836 Biological Products, (No Diagnostic Substances)